Several years ago (2002) I lost a chunk of change in a company (Cygnus) that manufactured the "Glucowatch" which used transdermal phoresis to measure glucose in a non-invasive manner. The company failed because the technology was too young, inaccurate and cumbersome (the units required disposable pads, as I recall). Cygnus flopped, but clearly I thought the idea had merit. Perhaps now, 12 years later, the idea's time has come.
Post by dreamboatcruise on Mar 16, 2015 12:01:06 GMT -5
If it works it would be a great advance.
If this were on the market I would push my own mother to get one and go on Afrezza. She is very borderline (A1C 6.9 last check) with doctor that doesn't seem overly concerned. My mother is somewhat blood phobic, so even with modern glucose meters/strips that is a barrier to getting her on Afrezza. For the time being she seems content to accept her doctor's view of anything under 7.0 as ok.
I am posting the below information here (but I had already posted it somewhere else as a separate tread). Some may think glucose monitoring (and their companies) should go under another heading like "resource centre' or 'other ideas' but I would argue CGM are a fundamental part of what will drive Afrezza in both type 1 and type 2s (but for different reasons). Administrators are obviously free to put it where they see fit...
It would be interesting to really understand what researchers (academic, Pharma and maybe even diabetics themselves: see below story) are planning to do with this disruptive and powerful new tool. As I keep boringly repeating the CGM is our friend. A non invasive and accurate CGM will be our best friend forever and probably directly or indirectly revolutionize the diabetic world. By using CGMs so much stuff we don't know about diabetes is now within reach. Researchers and patients themselves should and will have an extraordinary research opportunity that will only benefit smart physiological drugs like Afrezza. Using CGM I could very easily come up with more then a few research ideas that could show how different and superior Afrezza is to regular prandial insulins. I can only imagine what Mannkind and Sanofi have come up with. Same goes for academia and so many important public health policies (HbA1C vs CGM, HbA1C and CGM and good control/ different outcomes on different drugs, CMG and quality of life in diabetics, CMG and Afrezza for quality of life in type 1s etc.). I am actually almost jealous of those who will have the opportunity to do all these studies.
It would be interesting if a few like minded participants would informally want to share in building our collective knowledge on this topic. It involves knowledge of various different fields (IT, medicine, social media, hardware etc) to fully come to understand this but I am more and more certain that it could be highly interesting (and potentially rewarding). CGM are very easily as disruptive as Afrezza and if I am right about this we are only seeing the tip of the iceberg in this field. There is a reason Samsung, Apple, Google to name only a few of the big ones are so interested in all this...
Previously posted on another tread: For all those who are interested in glucose monitors. The article by Diabetes Mine is about an idea or start up by Jeff Dachis: a newly diagnosed type 1/ LADA who happens to be ex CEO (and cofounder) of Razorfish. I think these types of initiatives are worth following closely. This one is embryonic obviously but this is, to me anyway, one of the important types of 'digital directions' health care needs to take if we ever want to empower patients to have the data to make the changes that many of us (like Jeff Dachis explains in the below article) think the system needs.
OneDrop: A Newly Diagnosed Digital Guru’s Big Diabete Written by Amy Tenderich | Published on March 19, 2015
Jeff Dachis is a really smart guy. He’s the co-founder and former CEO of Razorfish, the world’s leading global digital marketing solutions company, and a “serial entrepreneur” who advises investors on a number of companies that wield technology to disrupt traditional industries. Jeff Dachis OneDrop
Now, he’s also one of us -- diagnosed with type 1 LADA diabetes about 18 months ago. Not surprisingly, he almost immediately went to work on a Big Idea to disrupt diabetes care and the system supporting it.